The Wolverine Stack (BPC-157 + TB-500): What It Is and What the Evidence Shows

“Wolverine stack” is one of the most searched terms in recovery peptides, and one of the most misleadingly sold. Most pages that explain it slide quickly into dosing charts, reconstitution maths or an invitation to book a clinic appointment. This page does none of that. It explains what the stack is, where the name comes from, how the tiered versions (GLOW and KLOW) fit in, what the evidence actually supports, and where it all stands legally, so you can read the claims for yourself.

The Wolverine stack is a combination of two separate peptides taken together, not a single product. It pairs BPC-157, a 15-amino-acid peptide studied mainly for soft-tissue and gut repair, with TB-500, a synthetic fragment related to the protein thymosin beta-4. Each is a distinct compound with its own research record and its own legal status; the “stack” is simply the convention of using them at the same time.

The nickname comes from the comic-book character famous for rapid self-healing, and it tells you everything about how the pairing is marketed and nothing about what it does. The term began in performance, biohacking and recovery communities as shorthand for a fast-healing combination, then was adopted by clinics and vendors as a ready-made product name. It is now one of the most searched phrases in the recovery-peptide space, which is exactly why almost every peptide seller offers a version of it.

Each peptide has its own full profile elsewhere on this site: everything known about BPC-157 and what the research says about TB-500. The stack itself is the marketing layer placed on top of both.

The bottom line: the Wolverine stack is two experimental peptides bundled under a memorable name, sold most heavily by the businesses that supply them.

The Wolverine stack is the entry point in a tiered range that adds peptides as it climbs. GLOW is the three-peptide version, which keeps BPC-157 and TB-500 and adds the copper peptide GHK-Cu. KLOW is the four-peptide version, which keeps all three and adds the anti-inflammatory tripeptide KPV. The naming is a marketing ladder, not an evidence ladder: each rung adds another compound, and another set of unknowns, rather than another layer of proof.

Stack	Peptides	What it adds	Marketed focus
Wolverine	BPC-157 + TB-500	The base pair	Soft-tissue and injury recovery
GLOW	BPC-157 + TB-500 + GHK-Cu	The copper peptide GHK-Cu	Recovery plus skin and collagen
KLOW	BPC-157 + TB-500 + GHK-Cu + KPV	The tripeptide KPV	Recovery, skin and inflammation

The bottom line: GLOW and KLOW are the Wolverine stack with more peptides and a heavier skin emphasis, not stronger proof of recovery.

The rationale is that the two peptides target different bottlenecks in healing. BPC-157 is proposed to act locally, supporting blood vessel growth and restoring blood flow to a damaged area, while TB-500 is proposed to act more systemically, encouraging the migration of the repair cells that rebuild tissue. The pitch is that these two bottlenecks are linked: blood flow without cell movement leaves nutrients arriving with nothing to use them, and cell movement without blood flow leaves repair cells starved, so a stack that covers both is meant to avoid the stalled, half-healed state.

It is a clean mechanistic story, and that is exactly why it sells. But it is a theory built by adding together what each peptide does separately in animal studies, not something shown for the combination in people. The detailed biology of each compound, and the genuine differences between them, are set out in how the two peptides compare head to head.

The bottom line: the “complementary mechanism” argument is a plausible hypothesis assembled from single-peptide animal data, not a tested property of the stack.

There are no human clinical trials of the BPC-157 plus TB-500 combination. The evidence base is entirely preclinical and comes from each peptide studied on its own. A 2025 systematic review by Vasireddi and colleagues counted 36 BPC-157 studies, 35 of them in animals and one a small human trial in 12 patients. Thymosin beta-4, the parent molecule of TB-500, has its own largely preclinical literature and only limited human data, and none of that work tested the two peptides used together.

The bottom line: the stack has zero human trial evidence as a combination, and the single-peptide evidence behind it is overwhelmingly preclinical.

Neither peptide is an approved medicine, and both sit outside legal compounding pending review. Both BPC-157 and TB-500 were removed from the FDA’s restricted Category 2 list in April 2026, and both are scheduled for evaluation on Day 1 of the advisory committee meeting on July 23, 2026, where the committee will consider whether they belong on the compounding list. The category system is explained in the FDA’s compounding category system, the sequence of events in how these peptides lost and regained their compounding status, and the meeting itself in the upcoming advisory committee review.

For athletes the picture is simpler and harsher. Both peptides are banned by the World Anti-Doping Agency: BPC-157 falls under the S0 category for non-approved substances, and TB-500 under S2 for growth factors and related agents. A single positive test from either component carries the same consequences as any other doping violation, so a “recovery” stack can end a sporting career rather than extend it. Full US context sits in the current US legal status of research peptides.

The bottom line: the Wolverine stack is two unapproved compounds, both under FDA review and both prohibited in competitive sport.

The most asked questions about the Wolverine stack have short answers: there is no proven advantage over either peptide used alone, no established human safety profile, and no shortcut around verifying the source.

Why is it called the Wolverine stack?

The name borrows the comic-book character associated with rapid self-healing, and it is purely a marketing label that spread through performance and biohacking communities before vendors adopted it as a product name. It signals the promise being sold, not any tested healing speed.

Is the Wolverine stack better than either peptide alone?

There is no comparative evidence showing that the combination outperforms either peptide used singly. The claim of synergy is a mechanistic argument, not a trial result, and the same is true of the GLOW and KLOW upgrades that add more compounds on top.

Is buying a pre-mixed blend the same as buying the peptides separately?

Not exactly. A pre-mixed Wolverine, GLOW or KLOW vial fixes the ratio of each peptide in advance, and those ratios are set by the seller, not by any clinical standard. As noted above, the GLOW and KLOW blends in particular lean heavily on GHK-Cu, so a blend can be weighted toward skin remodeling rather than the repair pair a buyer thinks they are getting.

Is it safe?

No large human safety dataset exists for either peptide, and none at all for the combination. Combining two experimental compounds, or three and four in GLOW and KLOW, stacks their unknowns rather than averaging them. The honest answer is that long-term safety in people is not established.

How would someone know a vial is genuine?

The only meaningful safeguard is independent laboratory testing, and a multi-peptide blend is harder to verify than a single compound because every component has to be confirmed. Read how to assess a peptide vendor and reading a certificate of analysis properly before trusting any supplier’s claims.

Where does the stack sit among other recovery peptides?

BPC-157 and TB-500 are two of several compounds marketed for tissue repair, each with a different evidence quality. The fuller landscape, including how their evidence compares with copper peptides and others, is mapped across the wider family of recovery peptides.